ÂÜÀòÂÒÂ×

Hemmel Amrania PhD is a Breast Cancer Diagnostics Expert with a diverse work experience. Starting in 2005 as a Clinical Research Associate at Cancer Research UK (CRUK), Amrania then moved to Charing Cross Hospital as a Clinical Research Associate in 2015. In the same year, Amrania took on the role of Manager at SEMdoctor. In 2016, Amrania became the Director of Business Development at LightFi, and in 2017 was a Physicist - Cancer Diagnostics Development at Imperial College London, as well as a Medical Technology Consultant at Imperial Innovations Investment Management. In 2021, Amrania joined Y Combinator as part of the YC Summer 21 Batch and is currently the Chief Executive Officer at Digistain. Throughout their career, Amrania has been certified in clinical trials design, a LabView Developer, and has completed statistics training for analysing clinical trial data. They have also successfully recruited senior clinicians to collaborate in clinical studies, written and submitted grant proposals to generate £500K of project funding, pitched to corporate partners, and managed ethics proposals for clinical research.

Hemmel Amrania holds a PhD in Physics from Imperial College London, where they studied Infrared Optics and Lasers, Biomedical Imaging, and Cancer Research from 2004 to 2008. Hemmel also holds a DEA/Masters from Ecole Superieure d'Optique, Universite Paris Sud XI, which they obtained in 2003-2004 for Optique et Photonique. Hemmel completed their MSci in Physics from Imperial College London in 1999-2003.